ArticlesFavipiravir, camostat, and ciclesonide combination therapy in patients with moderate COVID-19 pneumonia with/without oxygen therapy: An open-label, single-center phase 3 randomized clinical trial
Under a Creative Commons license
open access
Keywords
COVID-19
Camostat
Ciclesonide
Combination therapy
Favipiravir
Hospital stay
Randomized controlled trial
SARS-CoV-2
Cited by (0)
© 2022 The Author(s). Published by Elsevier Ltd.